The expansion of DNAbilize® technology into obesity represents a significant strategic move for Bio-Path Holdings, potentially opening new revenue streams and markets. This diversification beyond oncology could positively impact investor sentiment and the stock price in the short term. The announcement of Q3 2024 financial results also provides investors with updated financial performance data.